Regeneron Says U.S. FDA Halts Pain-Drug Study Because of Bone Death Issue

Published December 30, 2010

Regeneron Says U.S. FDA Halts Pain-Drug Study Because of Bone Death Issue
Regeneron Pharmaceuticals Inc. said U.S. regulators halted development of its experimental pain killer after a similar treatment caused the death of bone tissue in another drugmaker’s study.
Read more on Bloomberg

Santarus climbs on FDA submission
BOSTON (MarketWatch) — Shares of Santarus Inc. climbed 14% in premarket trading Tuesday on news that it and partner Pharming NV have submitted an application to U.S. regulators for the approval of the drug Rhucin for the treatment of the rare and potentially deadly disorder hereditary angioedema. Santarus has licensed certain commercial rights to the product from Pharming. The European Union …
Read more on Market Watch

Blog » Prep Sports
Robert Weiner was spokesman for the White House National Drug Policy Office and directed WADA media outreach at the Salt Lake Olympics in 2002 and White House Olympics drug media at Sydney 2000. He assisted in creation of WADA and USADA.
Read more on The Salt Lake Tribune